查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553610

心绞痛药物市场规模、份额、趋势分析报告：按类型、药物类别、分销管道、地区和细分市场预测，2024-2030

Angina Pectoris Drugs Market Size, Share & Trends Analysis Report By Type (Stable Angina, Unstable Angina), By Drug Class (Beta Blockers, Anticoagulants), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

心绞痛药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球心绞痛药物市场规模预计将达到157.1亿美元，2024年至2030年复合年增长率为4.0%。

全球心绞痛市场是由对缓解疾病和标靶治疗的需求、医疗保健支出的增加以及新兴市场有效治疗方法的可用性所推动的。

此外，心绞痛盛行率和发病率的上升预计将推动市场成长。在美国、英国、德国、法国、义大利、西班牙和日本等新兴市场，慢性稳定型狭心症的盛行率为2.0%至4.0%。男性和女性心绞痛盛行率均随年龄增加而快速增加，其中男性45至54岁为2.0至5.0%，男性65至74岁为10.0至20.0%，女性45至54岁为0.1至1.0% %， 74 岁时为65 - 10.0 至15.0%。这种疾病的症状可以透过健康的生活方式来控制。

心绞痛药物市场亮点

  • 在心绞痛药物市场中，稳定型心绞痛领域2023年占销售额的52.2%。患有慢性稳定型狭心症的患者数量正在增加，其中近一半将其发展为缺血性心臟疾病的早期症状。
  • 2023年， β阻断剂在心绞痛市场占有主导地位，销售份额为38.8%。该细分市场的成长主要是由于其越来越多地被用作心绞痛的一线治疗药物。
  • 收益占有率%。这是因为在基础设施先进、设备充足的医院中，寻求心绞痛治疗的患者数量不断增加。
  • 北美心绞痛药物市场主导全球心绞痛药物市场，2023年收益占有率超过40.0%。对微创治疗的需求不断增长预计将在预测期内推动市场成长。
  • 亚太地区心绞痛药物市场预计将以 5.5% 的复合年增长率在全球心绞痛药物市场中成长最快。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章心绞痛药物市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 心绞痛药物市场分析工具
    • 波特的分析
    • PESTEL分析

第四章心绞痛药物市场：按类型估计和趋势分析

  • 细分仪表板
  • 心绞痛药物市场：2023 年和 2030 年按类型分類的变化分析
  • 稳定型心绞痛
  • 不稳定型心绞痛
  • 微血管性心绞痛
  • 变异型心绞痛

第五章心绞痛药物市场：依药物类别估计与趋势分析

  • 细分仪表板
  • 心绞痛药物市场：2023 年和 2030 年按药物类别分類的波动分析
  • β受体阻断剂
  • 钙拮抗剂
  • 硝酸盐
  • 抗凝血物
  • 抗血小板药物
  • 其他药物类别

第六章心绞痛药物市场：依通路估算与趋势分析

  • 细分仪表板
  • 心绞痛药物市场：2023 年和 2030 年按分销管道分類的波动分析
  • 医院药房
  • 零售药房
  • 网路药房

第七章心绞痛药物市场：区域估计与趋势分析

  • 2023 年及 2030 年心绞痛药物市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Pfizer Inc.
    • Bayer AG
    • AstraZeneca
    • Gilead Sciences
    • Novartis AG
    • GlaxoSmithKline Plc.
    • Merck &Co., Inc.
    • Amgen Inc.
    • Eli Lilly and Company
    • Otsuka Pharmaceutical Co., Ltd.
    • Sanofi SA
    • Boehringer Ingelheim International GmbH
简介目录
Product Code: GVR-2-68038-045-3

Angina Pectoris Drugs Market Growth & Trends:

The global angina pectoris drugs market is expected to be valued at USD 15.71 billion by 2030, registering a CAGR of 4.0% from 2024 to 2030, as per a new report by Grand View Research, Inc. The global angina pectoris market is collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare and availability of effective treatment methods across the emerging markets.

Additionally, the rising prevalence and incidence of angina pectoris is anticipated to fuel the market growth. Chronic stable angina pectoris has a prevalence of 2.0-4.0% in developed markets such as the U.S., the U.K., Germany, France, Italy, Spain and Japan. The prevalence of angina pectoris rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74, and from 0.1-1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74. The disease symptoms can be managed by following a healthy lifestyle.

Angina Pectoris Drugs Market Report Highlights:

  • The stable angina segment dominated the angina pectoris drug market with a revenue share of 52.2% in 2023. The number of patients suffering from chronic stable angina is rising, and almost half of these patients have it as the initial sign of ischemic heart disease.
  • Beta blockers dominated the angina pectoris market in 2023 with a revenue share of 38.8%. Segment growth is primarily driven by its increasing adoption as a first-line therapy for angina pectoris.
  • Hospital pharmacies dominate the angina pectoris drugs market with a revenue share of 48.5% in 2023. This can be attributed to the fact that hospitals equipped with advanced infrastructure and suitable facilities are witnessing a rise in the number of patients seeking treatment for angina pectoris disorders.
  • North America angina pectoris drugs market dominated the global angina pectoris drugs market with a revenue share of over 40.0% in 2023. The increasing demand for minimally invasive procedures is expected to drive the market's growth in the forecast period.
  • Angina pectoris drugs market in Asia Pacific is expected the fastest growth in the global angina pectoris drugs market with a CAGR of 5.5%.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Angina Pectoris Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Angina Pectoris Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Angina Pectoris Drugs Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Angina Pectoris Drugs Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Stable Angina
    • 4.3.1. Stable Angina Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Unstable Angina
    • 4.4.1. Unstable Angina Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Microvascular Angina
    • 4.5.1. Microvascular Angina Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Prinzmetal Angina
    • 4.6.1. Prinzmetal Angina Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Angina Pectoris Drugs Market: Drug Class Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Angina Pectoris Drugs Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Beta Blockers
    • 5.3.1. Beta Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Calcium Antagonists
    • 5.4.1. Calcium Antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Nitrates
    • 5.5.1. Nitrates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Anticoagulants
    • 5.6.1. Anticoagulants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Anti-Platelets
    • 5.7.1. Anti-Platelets Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Other Drug Classes
    • 5.8.1. Other Drug Classes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Angina Pectoris Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Angina Pectoris Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacy
    • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Angina Pectoris Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Angina Pectoris Drugs Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Pfizer Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/Strategic Initiatives
    • 8.4.2. Bayer AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/Strategic Initiatives
    • 8.4.3. AstraZeneca
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/Strategic Initiatives
    • 8.4.4. Gilead Sciences
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/Strategic Initiatives
    • 8.4.5. Novartis AG
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/Strategic Initiatives
    • 8.4.6. GlaxoSmithKline Plc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/Strategic Initiatives
    • 8.4.7. Merck & Co., Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/Strategic Initiatives
    • 8.4.8. Amgen Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/Strategic Initiatives
    • 8.4.9. Eli Lilly and Company
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/Strategic Initiatives
    • 8.4.10. Otsuka Pharmaceutical Co., Ltd.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/Strategic Initiatives
    • 8.4.11. Sanofi S.A.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/Strategic Initiatives
    • 8.4.12. Boehringer Ingelheim International GmbH
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/Strategic Initiatives